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Currently, refractory lymphoma or advanced solid tumors
have an unfavorable prognosis as conventional therapies
are often not curative while providing high levels of
toxicity. Indeed, the overall survival of these patients is
relatively short with a poor quality of life. This clinical
evidence generates a relevant unmet medical need. In
the last few years, a renewed interest on adoptive cellu-
lar therapies emerged in the field of tumor-immunology
due to the remarkable advances in regard to our know-
ledge of the mechanisms employed by immune system
to fight cancer counterbalanced by the pathogenic loops
deployed by tumors to escape immune responses. All these
gained insights on cancer physiopathology greatly pushed
the development of novel technologies in biomedical field
that, in turn, led to the discovery of new categories of drugs
and alternative therapeutic approaches. Indeed, the use of
check-point inhibitors, T cells with engineered chimeric
antigen receptors (CARs) and bi-specific T cell engagers
(BiTE) showed impressive therapeutic potentials in the
cure of advanced tumors and are currently being included
in the in the armamentarium of clinicians [1].
Among the different approaches of anti-tumor adoptive
cell transfer, allogeneic stem cell transplantation (allo-SCT)
represents the first and most consolidated form of im-
munotherapy on the basis of its graft versus tumor (GvT)
effect. In this context, immune cell allo-reactivity can
be either associated with antigen presentation exerted
by class-I major histocompatibility complex (MHC-I)
as in the case of CD8 and CD4 T cells or, alternatively,
is antigen-independent as occurs with NK cells. How-
ever, GvT is counterbalanced by important toxicity and
non-relapse mortality [2]. Many attempts have been
performed, outside the allo-SCT contest, to exploit the
allo-reactivity activities of immune cells in order to
limit or bypass the toxicity experienced with allo-SCT.
In the early 80s’ donor lymphocyte infusions (DLI) with
allo-activated haplo-identical cells from family members
were infused in patients affected by hematological diseases
or solid tumors. These study demonstrated that a tempor-
ary mixed chimerism and tumor reduction often associ-
ated to graft versus host disease (GVHD) is possible [3, 4].
It has been also reported that, after standard chemother-
apy, the DLI with G-CSF-primed immune cells from re-
lated haplo-identical donors in aged patients affected by
acute myeloid leukemia can significantly reduces the rate
of tumor relapse [5].
NK cell recognition of “self” to ensure immunologic
tolerance versus autologous targets does not require a
prior sensitization and relies on large family of inhibi-
tory NK cell receptors (iNKRs) including Killer cell
immunoglobulin-like receptors (KIRs) and C-type lec-
tins that recognize specific alleles of MHC-I. The lack
of self-MHC-I on tumor-transformed cells makes them
susceptible to NK cell mediated lysis via the engage-
ment of several activating NK cell receptors (aNKRs)
that bind their ligands expressed on cancer cells (i.e.
missing self hypothesis) [6, 7]. Several protocols of
adjuvant therapies based on NK cell allo-reactivity have
been extensively used in clinics for both hematologic
and non-hematologic malignancies either alone or in
combination with antibodies and tumor-sensitizing drugs.
Indeed, adoptive cell transfer of allogeneic NK cells have
been used for the treatment of leukemia, colorectal cancer,
hepatocellular cancer, lymphoma and melanoma. The
major risk with these procedures is the development
of GVHD and several precautions have been put in place
to avoid this unfavorable clinical event, such as the
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infusion of CD3 depleted high pure NK cells or the selec-
tion of HLA matched donors [8]. Important insights into
NK cell function in cancer eradication originated from the
knowledge gained from mismatched NK cells in allo-SCT
setting, where these innate immune effectors mediate
a remarkable graft-versus-leukemia (GvL) effect towards
tumor cells of recipient without attacking their normal tis-
sues, thus limiting the onset of GVHD. Moreover, it has
been demonstrated HLA-mismatched NK cells in haploi-
dentical allo-SCT improve the overall survival of patients
affected by acute myeloid leukemia by controlling tumor
relapse without causing GVHD. The reduced priming of
alloreactive donor T cells as a consequence of NK cell
killing of recipient antigen-presenting cells and/or of a
direct inhibition of activated allo-reactive T cells have been
postulated as explanation of the low frequency of GVHD
[9–13]. However, a recent study reported that the infusion
of allogeneic IL-15 plus 4-1BBL activated human NK cell-
based DLI induced acute GVHD in five out of nine pa-
tients affected by solid tumors [14]. Finally, several other
variables hampering NK cell allo-reactivity against cancer
should be considered. Among these, there are the ability
of NK cell to infiltrate the tumor mass via the expression
of homing receptors (i.e. chemokines or others) as well as
the capacity of cancer cells to impair NK cell effector-
functions or to became resistant to NK cell lysis (i.e.
induction of inhibitory immunologic pathways or lack of
expression of aNKR ligands on their surface).
In the paper published by Yang Y. et al. [15] in this
issue of Cancer Immunology research, NK cells from
random and fully mismatched donors were first selected
and expanded to be then infused in patients with either
solid tumors (n = 18) or lymphomas patients (n = 2) in
the context of a phase I clinical trial. After testing esca-
lated doses of administered NK cells, authors did not re-
port a maximum tolerated dose (MTD) as only grade 1
and 2 toxicity was observed in the absence of GVHD.
The study also shows that the “safe” dose of adoptively
transferred NK cells that can be infused up to 3 times at
the dose of 3 x 107 cells/kg/week. Another important
point addressed by this work is the persistence of fully
mismatched NK cells in the recipients associated to their
anti-tumor effector-functions. Allo-reactive NK cells were
detected in the peripheral blood of recipients up to 4 days
after infusion with only 8 patients that achieved disease
stabilization while 9 progressed. Based on these data, it
can be drawn that the lifespan of mismatched NK cells is
quite short as they are quickly rejected by recipient
immune system. On the other hand, considering the all
patients were affected by advanced solid tumors, disease
stabilization can be considered an encouraging result
likely associated with the infusion of allo-reactive NK cells
endowed with great anti-tumor potential. Moreover, as
also previously reported [11], Yang Y. et al. postulate that
the simultaneous administration of immunosuppressive
drugs can prolong the persistence of infused cells and
boost the efficacy. Finally, the choice of random healthy
donors represents another important information provided
by this clinical trial to, at least try, resolve the problem of
finding a reliable and effective source of alloreactive NK
cells. As reported in haploidentical clinical trials of allo-
SCT [10], this strategy is aimed to develop a quick and
“low cost/low-tech” process to generate clinical grade anti-
cancer NK cells. Indeed, this phase I trial confirm that NK
cells from random donors are safe without major toxic ef-
fects, thus advocating for larger studies to confirm their
clinical efficacy. The exposure to cytokines, viral antigens
and haptens is associated with both modulation of NK
cell effector function and with the generation of a
newly disclosed subset of CD57pos/NKG2Cpos/KIRpos
NK cells endowed with adaptive traits [16, 17]. Hence,
further investigation are required to better determine
the impact of these “memory-like” NK cells in allo-reactive
response against cancer cells occurring in a malignant
microenvironment enriched with several immunogenic
stimuli such as viruses or cancer-induced haptens or in-
flammatory soluble factors.
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